DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC
- First Posted Date
- 2013-03-07
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 37
- Registration Number
- NCT01806740
- Locations
- 🇰🇷
Guerbet Korea, Seoul, Gangnam Gu, Korea, Republic of
Hepatic Xenetix-CT Perfusion
- First Posted Date
- 2012-07-13
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 96
- Registration Number
- NCT01639703
- Locations
- 🇨🇭
Zurich University Hospital, Zurich, Switzerland
🇰🇷SNUH, Seoul, Korea, Republic of
🇦🇹AKH, Vienna, Austria
Observational Post-marketing Study on the Safety and Efficacy of Dotarem® (SECURE Study)
- Conditions
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 35921
- Registration Number
- NCT01523873
- Locations
- 🇫🇷
Hôpital Necker, Paris, France
🇦🇷Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
🇮🇳Bombay Hospital Institute of Medical Sciences, Mumbai, India
Observational Study on the Incidence of NSF in Renal Impaired Patients Following Dotarem Administration
- Conditions
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 540
- Registration Number
- NCT01467271
- Locations
- 🇦🇷
Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
🇺🇸University of Texas Health Science Center, San Antonio, Texas, United States
🇧🇪H. Hartziekenhuis, Roeselare, Belgium
Safety and Dialysability of Dotarem® in Dialysed Patients
- Conditions
- Interventions
- First Posted Date
- 2011-10-10
- Last Posted Date
- 2015-07-08
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 10
- Registration Number
- NCT01449266
- Locations
- 🇧🇪
Clinical Pharmacology Unit Antwerp, Antwerp, Belgium
Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography
- Conditions
- Interventions
- First Posted Date
- 2010-12-07
- Last Posted Date
- 2015-12-16
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 468
- Registration Number
- NCT01255722
- Locations
- 🇫🇷
CHU Rouen - Hopital Charles Nicolle, Rouen, France
🇫🇷La Timone Adultes, Marseille, France
🇫🇷Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France
Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis
- Conditions
- Interventions
- First Posted Date
- 2010-12-06
- Last Posted Date
- 2019-05-31
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 351
- Registration Number
- NCT01254552
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions
- Conditions
- Interventions
- First Posted Date
- 2010-09-30
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 416
- Registration Number
- NCT01211873
- Locations
- 🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
🇦🇹Medical University of Vienna, Vienna, Austria
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients
- First Posted Date
- 2010-03-25
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 100
- Registration Number
- NCT01092754
- Locations
- 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Cardinal Glennon Childrens Hospital, Saint Louis, Missouri, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2012-12-11
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 189
- Registration Number
- NCT01026389
- Locations
- 🇦🇹
AKH hospital, Wien, Austria